Abivax (NASDAQ:ABVX – Get Free Report)‘s stock had its “buy” rating reaffirmed by Guggenheim in a research note issued on Tuesday, Benzinga reports. They presently have a $175.00 price target on the stock. Guggenheim‘s target price would suggest a potential upside of 87.19% from the company’s current price.
ABVX has been the topic of several other reports. Barclays reaffirmed an “overweight” rating and set a $148.00 target price on shares of Abivax in a report on Tuesday, September 22nd. Truist Financial cut their price target on Abivax from $155.00 to $151.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. The Goldman Sachs Group started coverage on Abivax in a research report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price target on the stock. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Finally, Piper Sandler lifted their price objective on Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $155.00.
View Our Latest Analysis on Abivax
Abivax Stock Performance
Shares of ABVX stock traded up $0.90 on Tuesday, hitting $93.49. The company’s stock had a trading volume of 947,951 shares, compared to its average volume of 1,427,088. The stock’s 50 day moving average is $105.10 and its 200-day moving average is $114.33. Abivax has a fifty-two week low of $69.81 and a fifty-two week high of $148.83. The company has a market capitalization of $8.18 billion, a PE ratio of -15.43 and a beta of 1.14.
Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to analyst estimates of $0.80 million. On average, research analysts forecast that Abivax will post -4.04 earnings per share for the current year.
Hedge Funds Weigh In On Abivax
Hedge funds and other institutional investors have recently made changes to their positions in the company. GHP Investment Advisors Inc. raised its position in Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Abivax in the 2nd quarter valued at $30,000. Assetmark Inc. boosted its holdings in shares of Abivax by 41.5% in the 1st quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after purchasing an additional 260 shares in the last quarter. Troluce Capital Advisors LLC bought a new position in shares of Abivax in the 2nd quarter valued at $133,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Abivax in the 1st quarter valued at $208,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.
About Abivax
Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.
Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.
Read More
- Five stocks we like better than Abivax
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
